Axitinib for metastatic non-clear cell renal cell carcinoma

Results from a phase 2 clinical trial of axitinib (Inlyta) for patients with advanced non-clear cell renal cell carcinoma (RCC) who had failed prior treatment with temsirolimus (Torisel) are promising in terms of objective response rate (ORR) and progression-free survival (PFS).  Forty patients with metastatic or recurrent non-clear cell RCC who had failed treatment with […]

read more

Axitinib plus pembrolizumab combination shows promise for advanced kidney cancer

Data from a recent phase 1b study has shown that a combination of axitinib and pembrolizumab treatment for advanced renal cell carcinoma (RCC) is safe and tolerable, and exhibits promising anti-tumour activity in previously untreated patients. The study data were presented at the 2018 Genitourinary Cancers Symposium held in San Francisco last week. The researchers […]

read more

New first-line treatment option for advanced kidney cancer available on the NHS

Today, the National Institute for Health and Care Excellence (NICE) have recommended tivozanib (Fotivda) as a new first-line treatment option for people with advanced renal cell carcinoma (RCC) for use within NHS England and Wales. This follows a protracted appraisal process involving three committee meetings over 20 months while the process was suspended to allow the manufacturer to submit further […]

read more
Showing 51 to 53 of 53 results